This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Ihle, N. T. Articles by Powis, G. Search for Related Content PubMed PubMed Citation Articles by Ihle, N. T. Articles by Powis, G.

Mutations in the Phosphatidylinositol-3-Kinase Pathway Predict for Antitumor Activity of the Inhibitor PX-866 whereas Oncogenic Ras Is a Dominant Predictor for Resistance

¹ M. D. Anderson Cancer Center, Houston, Texas; ² Department of Chemistry, University of Pittsburgh, Pittsburgh, Pennsylvania; ³ Virginia Commonwealth University School of Medicine, Richmond, Virginia; and ⁴ Oncothyreon, Inc., Bellevue, Washington

Requests for reprints: Garth Powis, M. D. Anderson Cancer Center, FC-6.3044, 1515 Holcombe Boulevard, Houston, TX 77030. Phone: 713-745-3366; Fax: 713-745-1710; E-mail: gpowis{at}mdanderson.org.

Key Words: PX-866 • PI3K • Akt • Ras • response

The novel phosphatidylinositol-3-kinase (PI3K) inhibitor PX-866 was tested against 13 experimental human tumor xenografts derived from cell lines of various tissue origins. Mutant PI3K (PIK3CA) and loss of PTEN activity were sufficient, but not necessary, as predictors of sensitivity to the antitumor activity of the PI3K inhibitor PX-866 in the presence of wild-type Ras, whereas mutant oncogenic Ras was a dominant determinant of resistance, even in tumors with coexisting mutations in PIK3CA. The level of activation of PI3K signaling measured by tumor phosphorylated Ser⁴⁷³-Akt was insufficient to predict in vivo antitumor response to PX-866. Reverse-phase protein array revealed that the Ras-dependent downstream targets c-Myc and cyclin B were elevated in cell lines resistant to PX-866 in vivo. Studies using an H-Ras construct to constitutively and preferentially activate the three best-defined downstream targets of Ras, i.e., Raf, RalGDS, and PI3K, showed that mutant Ras mediates resistance through its ability to use multiple pathways for tumorigenesis. The identification of Ras and downstream signaling pathways driving resistance to PI3K inhibition might serve as an important guide for patient selection as inhibitors enter clinical trials and for the development of rational combinations with other molecularly targeted agents. [Cancer Res 2009;69(1):143–50]

This article has been cited by other articles:

				T. D. Le Cras, T. R. Korfhagen, C. Davidson, S. Schmidt, M. Fenchel, M. Ikegami, J. A. Whitsett, and W. D. Hardie Inhibition of PI3K by PX-866 Prevents Transforming Growth Factor-{alpha}-Induced Pulmonary Fibrosis Am. J. Pathol., February 1, 2010; 176(2): 679 - 686. [Abstract] [Full Text] [PDF]

				P. Vigneri, F. Frasca, L. Sciacca, G. Pandini, and R. Vigneri Diabetes and cancer Endocr. Relat. Cancer, December 1, 2009; 16(4): 1103 - 1123. [Abstract] [Full Text] [PDF]

				U. McDermott and J. Settleman Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology J. Clin. Oncol., November 20, 2009; 27(33): 5650 - 5659. [Abstract] [Full Text] [PDF]

				A. C. Faber, D. Li, Y. Song, M.-C. Liang, B. Y. Yeap, R. T. Bronson, E. Lifshits, Z. Chen, S.-M. Maira, C. Garcia-Echeverria, et al. Differential induction of apoptosis in HER2 and EGFR addicted cancers following PI3K inhibition PNAS, November 17, 2009; 106(46): 19503 - 19508. [Abstract] [Full Text] [PDF]

				B. Markman, F. Atzori, J. Perez-Garcia, J. Tabernero, and J. Baselga Status of PI3K inhibition and biomarker development in cancer therapeutics Ann. Onc., August 27, 2009; (2009) mdp347v1. [Abstract] [Full Text] [PDF]

				T. Walker, C. Mitchell, M. A. Park, A. Yacoub, M. Graf, M. Rahmani, P. J. Houghton, C. Voelkel-Johnson, S. Grant, and P. Dent Sorafenib and Vorinostat Kill Colon Cancer Cells by CD95-Dependent and -Independent Mechanisms Mol. Pharmacol., August 1, 2009; 76(2): 342 - 355. [Abstract] [Full Text] [PDF]

				F. I. Raynaud, S. A. Eccles, S. Patel, S. Alix, G. Box, I. Chuckowree, A. Folkes, S. Gowan, A. De Haven Brandon, F. Di Stefano, et al. Biological properties of potent inhibitors of class I phosphatidylinositide 3-kinases: from PI-103 through PI-540, PI-620 to the oral agent GDC-0941 Mol. Cancer Ther., July 1, 2009; 8(7): 1725 - 1738. [Abstract] [Full Text] [PDF]